Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Pre-Operative fSRS for Brain Metastases

16 november 2026 bijgewerkt door: Northwell Health

Improving Outcomes in Patients With Metastatic Cancer to the Brain With Pre-Operative Fractionated Radiosurgery (fSRS): A Pilot Study

This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.

This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.

The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.

This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

12

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New York
      • New York, New York, Verenigde Staten, 10075
        • Lenox Hill Hospital, Northwell Health
        • Hoofdonderzoeker:
          • A. Gabriella Wernicke, MD, MS

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patient is ≥18 years old.
  • Radiographic confirmation of 1-5 brain metastases by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
  • The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
  • Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
  • All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
  • Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
  • Karnofsky Performance Status (KPS) ≥50 within 14 days prior to registration.
  • A negative urine or serum pregnancy test (for individuals of childbearing potential) ≤14 days prior to registration.
  • Patient or legally authorized representative provides study-specific informed consent before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.

Exclusion Criteria:

- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.

Note: Prior or current fSRS/SRS to other non-index lesions is allowed.

  • Evidence of leptomeningeal disease.
  • Any contraindication or inability to undergo MRI with contrast.
  • Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.

Note: Chemotherapy and immunotherapy outside of this window are allowed.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Pre-Operative fSRS Followed by Re-Section

This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy.

Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases.

Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.

Andere namen:
  • Brain Metastasis Resection

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Local Freedom from Progression (FFP) within the Resection Cavity
Tijdsspanne: 6, 12, 18, and 24 Months Post-Operative

The absence of new nodular contrast enhancement 2 mm or less from the resection cavity.

6, 12, 18, and 24 Months Post-Operative

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Leptomeningeal Disease (LMD)
Tijdsspanne: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years

Documented incidence of LMD on brain MRI imaging

From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
Incidence of Radiation Necrosis (RN)
Tijdsspanne: From post-operative (48-72 hours after surgery) through every 3 months for 2 years

Documented incidence of RN on brain MRI imaging

From post-operative (48-72 hours after surgery) through every 3 months for 2 years
Change in Neurocognitive Function
Tijdsspanne: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years

Assessed using the Montreal Cognitive Assessment (MoCA) score

Baseline, Post-Operative Visit, and Every 3 Months for 2 Years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
Tijdsspanne: Between Surgery and Post-Operative Visit

Comparison of pathological characteristics of resected brain metastasis with the primary tumor

Between Surgery and Post-Operative Visit
Correlation of Extent of Surgical Resection with Survival Outcomes
Tijdsspanne: From study registration until 2 years post-operative or death

Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS)

From study registration until 2 years post-operative or death

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2028

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

9 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 26-0403
  • 23-004 (Andere identificatie: Northwell Health Cancer Institute)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .